Victory Capital Management Inc. Has $11.67 Million Stock Holdings in IQVIA Holdings Inc. $IQV

Victory Capital Management Inc. reduced its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 5.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 61,416 shares of the medical research company’s stock after selling 3,582 shares during the period. Victory Capital Management Inc.’s holdings in IQVIA were worth $11,665,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Artisan Partners Limited Partnership acquired a new stake in shares of IQVIA in the second quarter valued at about $515,772,000. Norges Bank bought a new position in shares of IQVIA during the 2nd quarter worth about $270,160,000. AQR Capital Management LLC lifted its position in shares of IQVIA by 130.2% in the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock worth $245,099,000 after acquiring an additional 879,701 shares during the period. Laurel Wealth Advisors LLC grew its holdings in shares of IQVIA by 15,755.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 779,598 shares of the medical research company’s stock worth $122,857,000 after purchasing an additional 774,681 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of IQVIA by 22.8% during the second quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock valued at $492,659,000 after purchasing an additional 581,157 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on IQV. UBS Group lowered their price target on shares of IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Barclays raised shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target for the company in a research report on Friday, March 6th. Mizuho set a $215.00 price objective on IQVIA in a research note on Monday, February 23rd. Jefferies Financial Group cut their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Finally, Evercore reiterated an “outperform” rating and issued a $225.00 price target on shares of IQVIA in a research report on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, IQVIA presently has an average rating of “Buy” and a consensus target price of $229.13.

IQVIA Stock Performance

NYSE:IQV opened at $171.64 on Thursday. The stock has a market capitalization of $29.13 billion, a P/E ratio of 21.84, a price-to-earnings-growth ratio of 1.65 and a beta of 1.39. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04. The firm has a 50 day moving average of $204.05 and a 200-day moving average of $207.14.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. The firm had revenue of $4.36 billion during the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The business’s revenue was up 10.3% on a year-over-year basis. During the same period last year, the firm posted $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.